Recently, a meta-analysis by Katsanos et a. showed an increase in late mortality after paclitaxel administration (either with DES or DCB) in the peripheral field (SFA).
The topic is hot and deserves a deep analysis of the available data. For the moment, our position regarding DCB is that the technology, if used in expert hands and following the available position papers, is safe and effective for the treatment of lower extremity disease.
Please, take a look at the recently published editorial of F Fanelli, T Zeller and myself in the Journal of Endovascular therapy.
